457 Enteral Stenting Versus Gastrojejunostomy for Palliation of Malignant Gastric Outlet Obstruction

Alawad, Ahmad S.; Shin, Eun Ji; Bourdel, Nicolas; Kim, Katherine; Sharaiha, Reem Z.; Singh, Vikesh K.; Lennon, Anne Marie; Okolo, Patrick I.; Canto, Marcia I.; Khashab, Mouen A.

doi:10.1016/j.gie.2012.04.074

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alawad et al 19 retrospectively compared enteral stenting using self-expandable metallic stents (SEMS; n ϭ 120) with gastrojejunostomy (n ϭ 227) for palliation of malignant gastric outlet obstruction. Technical success was high in both groups, although significantly higher for gastrojejunostomy (99 vs. 96%; P ϭ 0.004).…”

Section: Local Advanced Gastric Cancermentioning

confidence: 99%

“…The 2012 Digestive Disease Week (DDW; [19][20][21][22] May, San Diego, California, USA) presented small-step advances in the field of non-Barrett's esophageal and gastric tumors. In patients with ear-nose-throat (ENT) cancer, narrow-band imaging (NBI) might be useful in endoscopic screening for early esophageal squamous neoplasia, but confirmation of its role has yet to be reported.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Non-Barrett's esophageal and gastric tumors: diagnosis and treatment

Ciocîrlan

Gincul

Lépilliez

et al. 2012

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Section: Local Advanced Gastric Cancermentioning

confidence: 99%

mentioning

confidence: 99%

Non-Barrett's esophageal and gastric tumors: diagnosis and treatment

Ciocîrlan

Gincul

Lépilliez

et al. 2012

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

“…Local advanced gastric cancer ! Alawad et al [19] retrospectively compared enteral stenting using self-expandable metallic stents (SEMS; n = 120) with gastrojejunostomy (n = 227) for palliation of malignant gastric outlet obstruction. Technical success was high in both groups, although significantly higher for gastrojejunostomy (99 vs. 96 %; P = 0.004).…”

mentioning

confidence: 99%

Non-Barrett's esophageal and gastric tumors: diagnosis and treatment

et al. 2012

View full text Add to dashboard Cite

DDW Highlights 860Early squamous esophageal cancer ! Screening for squamous esophageal dysplasia and early esophageal carcinoma relies mainly on Lugol chromoscopy. The procedure has been advocated in patients with personal history of squamous ENT cancer, and results from the European Society of Gastrointestinal Endoscopy (ESGE) trial of endoscopy screening (EUROSQUAM) are awaited. Lugol chromoscopy is best performed under sedation with tracheal intubation in order to prevent aspiration and avoid the chest discomfort experienced by patients. Therefore, newer technologies of virtual chromoscopy have been advocated. Nagami et al.[1] designed a prospective nonrandomized comparative study of NBI vs. Lugol chromoscopy to screen for squamous neoplasia in 202 patients (124 with history of ENT cancer and 78 with previous endoscopically resected esophageal cancer). One operator performed both investigations. A total of 113 suspicious lesions (brownish areas on NBI or unstained areas with or without pink coloration after Lugol chromoscopy) were biopsied. Of these, 31 were squamous lesions, all of which were detected by Lugol chromoscopy but only 28 by NBI. The sensitivities of the two respective examinations were reported to be comparable (P = 0.08). One should note that it is very difficult to design a noninferiority study of NBI vs. Lugol chromoscopy. Expected squamous neoplastic lesion prevalence is about 10 % in ENT cancer, of which only about 20 % are early carcinomas, and only 20 % of these are detected exclusively by Lugol staining. In order to obtain approximately 30 of these "supplementary" patients, a trial that included several thousand patients would need to be conducted. The gold standard used would also always be questionable, as false-negative lesions are obviously not biopsied, so an adequate follow-up of negative cases is warranted. We consider that the value of NBI in screening for esophageal squamous neoplastic lesions remains to be determined. Is there any survival benefit of screening in patients with ENT cancer? A retrospective study suggests that the answer might be positive. Lee et al. [2] compared the survival of patients with hypopharyngeal cancer following the introduction of an endoscopic esophageal screening policy in 2007. An historic cohort of 281 patients who did not undergo screening between 2003 and 2006 were compared with 320 patients screened for esophageal cancer between 2007 and 2010. Of the patients who underwent screening, 49 (27.2%; 95 % confidence interval [CI] 20.7 -33.7) had synchronous esophageal cancer, and the treatment plan was consequently changed for 42 of them. Patients who did not accept screening after 2007 had the same survival as patients before 2007 (P = 0.806). Patients screened after 2007 had better survival than unscreened paCiocirlan M et al. Diagnosis and treatment of non-arrett's tumors … Endoscopy 2012; 44: 860-864

show abstract

457 Enteral Stenting Versus Gastrojejunostomy for Palliation of Malignant Gastric Outlet Obstruction

Cited by 2 publications

References 0 publications

Non-Barrett's esophageal and gastric tumors: diagnosis and treatment

Non-Barrett's esophageal and gastric tumors: diagnosis and treatment

Non-Barrett's esophageal and gastric tumors: diagnosis and treatment

Contact Info

Product

Resources

About